Fibroelastosis Subendocardial

Subendocardial fibroelastosis (fibroelasticus subendocardialis) is a rare heart disease that is characterized by the formation of scar tissue in the subendocardium. This can lead to impaired heart function and an increased risk of cardiovascular complications.

Subendocardial fibroelastotic tissue usually appears as thickening and hardening of the heart wall, which can be detected by echocardiography. Patients may experience shortness of breath, rapid heartbeat, chest pain, and other symptoms associated with poor heart function.

Treatment for subendocardial fibroelastosis may include drug therapy, such as anticoagulants to reduce the risk of blood clots, as well as surgery, such as arrhythmia ablation or heart valve replacement.

However, although subendocardial fibroelastosis is a rare disease, it can lead to serious health consequences. Therefore, it is important to conduct regular examinations and monitor your health in order to promptly identify possible heart problems.

Fibroelastosis or Marfan syndrome is a genetically determined syndrome, clinically manifested by lesions of the skin, arteries, aorta (diaphragmatic) and their branches. These changes are caused by hyperelasticity and hyperconization, which in turn arise due to a defect in the synthesis or insufficient production, transmission and action of the neurogenic relaxation hormone - alpha-melanocin. Among adult patients, the prevalence of this syndrome is about 3%. In women it is more than 2 times higher compared to men. Along the course, progressive and benign variants of Marfan disease are distinguished.